**CASE REPORTS**

**Congenital Dermatofibrosarcoma Protuberans: A Case Report**

C Muniesa, N Curcó, X Pagerols, M García-Font, X Tarroch, and P Vives

**Introduction**

Dermatofibrosarcoma protuberans (DFSP) is a low-grade fibrohistiocytic tumor characterized by a high rate of local recurrence. It usually presents between 20 and 50 years of age and is rare in patients younger than 16 years. Even rarer are cases of congenital dermatofibrosarcoma and only 27 cases have been reported in the literature.1,2 We report the case of a 10-year-old boy with DFSP present since birth and no signs of recurrence to date.

**Case Description**

A 10-year-old boy from Morocco with no clinical history of interest consulted for a tumor on his left leg that was present from birth and had grown gradually. Physical examination showed an indurated plaque measuring 9 × 7.5 cm on the inner aspect of the left leg (Figure 1) with 2 peripheral atrophic areas revealing the underlying vascular network. In the center, there were 2 brownish-yellow tumor nodules measuring 1 cm in diameter and another, larger violaceous nodule (Figure 2). Palpation revealed the lesion to be firm and attached to the subcutaneous tissue. X-ray of the tibia and fibula and an ultrasound scan of the soft tissue were normal. A skin biopsy revealed an atrophic epidermis and a dense cellular infiltrate that extended deeply from the papillary dermis (Figure 3). The infiltrate was composed of spindle cells with an elongated nucleus arranged in short bundles in a storiform pattern (Figure 4). The immunohistochemical
study showed that the tumor cells were positive for CD34 and tenasin (Figure 5). The combination of histologic and immunohistochemical findings led to a diagnosis of DFSP, which was congenital in this case, given that it was present at birth. After diagnosis, the child underwent wide resection of the tumor. For personal reasons, the procedure was carried out at another center and, to date, we have no reports of a relapse.

Discussion

DFSP is a low-grade fibrohistiocytic tumor that was first described in 1924 by Darier and Ferrand with the name “progressive and recurrent dermatofibroma.” One year later, Hoffman reported 3 new cases and proposed the term dermatofibrosarcoma protuberans. This tumor is uncommon and represents 0.1% of malignant tumors. It usually presents between 20 and 50 years of age and is rare in children aged less than 16 years (6% of all cases). The congenital form is even more uncommon, with only 27 cases reported in the literature. In general, there is a greater prevalence in the white population and it is slightly more common in men, although congenital cases are more frequent in women. It is most often found on the trunk and proximal limbs—it is rare on the head and neck—and its clinical presentation is very varied. It usually presents as a violaceous or bluish erythematous plaque or macule that is vascular in appearance. It grows slowly over the years and small nodules appear on the plaque surface before becoming nodular or protuberant. The plaque is asymptomatic and indurated, although it can sometimes become ulcerated and painful. It occasionally persists as a nonprotuberant plaque, in which case it is known as atrophic DFSP. In these cases, it usually presents as a violaceous, depressed, and atrophic lesion similar to a scar, with no nodule. In clinical terms, it is often confused with sclerosing basal cell carcinoma, anetoderma, morphea, or a scar. Atrophic DFSP is particularly frequent in congenital cases and during infancy.

Diagnosis of DFSP is based on histology. The tumor cells are spindle-shaped with an elongated nucleus and are arranged in short bundles in a characteristic windmill or storiform pattern. There are few atypical cells and a very small number of mitotic figures. The pattern is one of infiltrative growth that generally extends to the deep
dermis and subcutaneous cellular tissue. The Bednar tumor is a histological variant of DFSP with melanin-containing dendritic cells between the spindle cells.\(^9\) Another subtype is the myxoid tumor, with areas of interstitial mucin between the spindle cells.\(^10\) In the immunohistochemical study, it is very important to highlight the positivity of tumor cells with the antibody for CD34, a surface antigen expressed in hematopoietic stem cells, the endothelia, and in the skin (around follicular structures, sebaceous glands, and sweat glands). This antigen may also be present in neoplasms, as is the case with DFSP, and is extremely helpful when differentiating between this and other fibrohistiocytic tumors. Tenascin is a stromal marker of connective tissue that is usually positive in DFSP cells, and this positivity characteristically extends to the subcutaneous cellular tissue. Vimentin is also positive and the other markers (factor XIIIa, S-100, actin, and desmin) are negative. In cytogenetic terms, DFSP is characterized by the reciprocal translocation t(17;22)(q22;q13) that generates a fusion between the gene encoding type 1 collagen on chromosome 17q and the gene for the B chain of platelet-derived growth factor located on chromosome 22q.\(^1,3,11\)

Clinical diagnosis of DFSP in infants or young people may be awkward because, in the early stages, the tumor often looks like a vascular malformation. The remaining differential diagnoses must be made with fibrohistiocytic tumors such as dermatofibroma, leiomyoma, neurofibroma, dermatomyofibroma, and, for infants, with infantile myofibromatosis and fibrous hamartoma of infancy.\(^1,2,7\) Dermatofibroma is a more nodular lesion that is limited to the dermis. If it does invade the subcutaneous cellular tissue, it does so via interlobular septa and, unlike DFSP, an immunohistochemical study shows that it is CD34-negative and factor XIIIa-positive. Leiomyoma is composed of spindle cells with cigar-shaped nuclei that are arranged parallel to the epidermis. If an immunohistochemical study is performed, it shows leiomyoma to be positive for desmin and caldesmon, both of which are negative in DFSP. Neurofibroma has smaller, wavy nuclei and is positive for S-100, an antibody that is consistently negative in DFSP. Dermatomyofibroma is an unusual tumor that presents as an asymptomatic slow-growing plaque. It is common on the neck and shoulders of young adults, particularly women. Histology shows the tumor to have a plaque-like appearance composed of bundles of monomorphic spindle cells arranged parallel to the epidermis. The cells have an eosinophilic cytoplasm and an elongated vesicular nucleus with 1 or 2 nucleoli and express smooth-muscle actin and vimentin. Infantile myofibromatosis is characterized by the appearance of nodular or tumor lesions that are firm and elastic and found mainly on the trunk, shoulders, and thighs. Solitary forms can affect the skin, bone, and viscera. Histology shows the spindle cells to have an eosinophilic cytoplasm and vesicular nuclei arranged in short interlaced bundles. The cellular aggregates are separated by fine bands of collagen and vascular spaces can often be observed in the center of the tumor. Immunohistochemistry shows the
cells to be positive for vimentin and actin. Fibrous hamartoma of infancy is almost completely restricted to prepubertal patients; its characteristic organoid pattern is made up of fibrous collagenous trabeculae, primitive mesenchymal cells, and mature adipose tissue, and it is easy to differentiate it from DFSP by optical microscopy.

Treatment involves wide resection of the tumor with a 2-3 cm margin including the superficial fascia. Radiotherapy is reserved for adjuvant therapy in the case of incomplete resections or large tumors. DFSP is a tumor characterized by marked local invasion and a high rate of local recurrences (between 20% and 50%), especially within the first 3 years after surgery. Mohs micrographic surgery has reduced the rate of recurrence to less than 2% and is considered the treatment of choice.1,9 Recent studies show that magnetic resonance imaging may be very helpful as a preoperative instrument for determining the extension and size of the tumor in order to plan surgery and prevent local recurrences.1 It can also help in postoperative follow-up to detect and monitor tumor recurrence. Clinical check-ups are recommended every 3 to 6 months during the first 3 years following surgery and every year thereafter. Metastasis of DFSP is extremely rare—it has been reported in 16% of patients—and indicates a poor prognosis.1,7 The lungs are the most common site of metastasis, by hematogenous spread, followed by metastases in regional lymph nodes, brain, bone, and heart.

Our most noteworthy conclusion is that, when faced with a child presenting plaques or cutaneous nodules—even congenital ones—with no clear clinical diagnosis, it is advisable to perform a biopsy. Furthermore, given the potential for aggressive local invasion and the high rate of recurrence in DFSP, diagnosis should be made early to facilitate suitable resection.

Conflicts of Interest
The authors declare no conflicts of interest.

References